Clinical Characteristics and Molecular Mechanism of Patients With Obstructive Sleep Apnea

November 29, 2025 updated by: Zhaohui Tong, Capital Medical University
To clarify the clinical features of patients with obstructive sleep apnea; To construct a multi-omics database of patients with obstructive sleep apnea, and compare the effects of different degrees of sleep apnea on prognosis, immunity, and metabolism. The medium and long-term prognosis, complications, comorbidities, risk factors, and immune and metabolic dynamics of patients with sleep apnea after treatment were studied. To elucidate the biomarkers and therapeutic targets associated with obstructive sleep apnea.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Zhiling Zhao
  • Phone Number: +86 186 1280 8859
  • Email: cysleep@163.com

Study Locations

  • China
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100020
        • Recruiting
        • Beijing Chaoyang Hospital Affiliated to Capital Medical University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Patients with obstructive sleep apnea.

Description

Inclusion Criteria:

  • Patients with suspected obstructive sleep apnea (OSA) admitted to the sleep center of the respiratory Department of Beijing Chaoyang Hospital, Capital Medical University.
  • Volunteer to participate in the study and sign an informed consent, and can complete at least 1 year of follow-up.

Exclusion Criteria:

  • Patients with obstructive sleep apnea who have been treated with impermanent positive pressure ventilation;
  • Pregnant or lactating women;
  • Patients with severe respiratory failure requiring mechanical ventilation;
  • Patients with severe heart, lung, liver, kidney, and central nervous system damage;
  • Refuse to participate in follow-up visits and/or take biological samples.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Healthy controls
Severe OSA
Non-severe OSA

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Multiple-omics features
Time Frame: Within 24 hours of admission，and samples of patients receiving treatment were also collected six months and one year after treatment
ELISA ,proteomics and metabolomics were performed on blood, saliva, urine
Within 24 hours of admission，and samples of patients receiving treatment were also collected six months and one year after treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Capital Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 7, 2023

Primary Completion (Estimated)

August 7, 2033

Study Completion (Estimated)

August 7, 2033

Study Registration Dates

First Submitted

January 3, 2024

First Submitted That Met QC Criteria

November 29, 2025

First Posted (Actual)

December 11, 2025

Study Record Updates

Last Update Posted (Actual)

December 11, 2025

Last Update Submitted That Met QC Criteria

November 29, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2023-ke-450

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Data will be available on reasonable request.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obstructive Sleep Apnea

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe